Stock INNO INNOCAN PHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

InnoCan Pharma Corporation Stock

Equities

INNO

CA45783P1027

Pharmaceuticals

Market Closed - Canadian Securities Exchange
Other stock markets
 03:56:47 2024-05-10 pm EDT 		5-day change 1st Jan Change
0.32 CAD -3.03% Intraday chart for InnoCan Pharma Corporation +18.52% +3.23%
May. 09 Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey CI
Apr. 22 InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 2.56 3.5 Sales 2023 13.66 18.67 Capitalization 62.67M 85.67M
Net income 2022 -3M -4.1M Net income 2023 -4M -5.47M EV / Sales 2022 15,473,821 x
Net cash position 2022 4.91 6.72 Net cash position 2023 3.85 5.27 EV / Sales 2023 4,588,686 x
P/E ratio 2022
-10.5 x
P/E ratio 2023
-12.8 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 77.04%
More Fundamentals * Assessed data

Chart InnoCan Pharma Corporation

Dynamic Chart

Latest news about InnoCan Pharma Corporation

Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey CI
InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain CI
InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University CI
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval MT
InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding CI
Innocan Pharma Corporation Announces Tissue Distribution Study of LPT-CBD to the Brain CI
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding CI
InnoCan Pharma Corporation Announces Study Findings That Lpt-Cbd Maintain Its Prolonged Release in Rabbits CI
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
InnoCan Pharma Brief: Says "Surge" in revenue Primarily attributable to "Robust" sales performance of Subsidiary, B.I. Sky Global Ltd. MT
InnoCan Pharma Brief: Reporting US$4.083 Million In Revenues for Q3 2023 Vs US$749,000 for Q3 2022, representing an increase of 445% MT
Innocan Pharma Corporation Announces Promising LPT-CBD Safety Indications CI
InnoCan Pharma Completes Second, Final Tranche of Financing; Down Over 3% MT
InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding CI
More news

Press releases InnoCan Pharma Corporation

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey AQ
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain AQ
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M AQ
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval. AQ
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million AQ
More press releases

News in other languages on InnoCan Pharma Corporation

InnoCan Pharma Corporation: Innocan Pharma meldet Durchbruch in einem vorklinischen Versuch: Durch die Injektion mit Liposom-CBD wird die Mobilität einer Eselin mit amputiertem Bein wiederhergestellt
InnoCan Pharma Corporation: Innocan Pharma leitet FDA-Zulassungsverfahren für Liposomen-Injektionstherapie gegen chronische Schmerzen ein
InnoCan Pharma Corporation: Innocan Pharma gibt die Gesamtergebnisse des Jahres 2023 bekannt Umsätze um das 6-Fache auf 13,7 Mio. $ gestiegen
InnoCan Pharma Corporation: Innocan Pharma ebnet Weg zu Chemie, Herstellung und Kontrollen (CMC) von LPT-CBD, den wichtigsten Meilensteinen für die FDA-Zulassung
InnoCan Pharma Corporation: Innocan Pharma meldet Abschluss der Privatplatzierung mit einem Bruttoerlös von rund 2 Millionen C$
More news

Quotes and Performance

1 day-3.03%
1 week+18.52%
Current month+14.29%
1 month+8.47%
3 months+1.59%
6 months-5.88%
Current year+3.23%
More quotes

Highs and lows

1 week
0.28
Extreme 0.275
0.33
1 month
0.25
Extreme 0.25
0.33
Current year
0.25
Extreme 0.25
0.34
1 year
0.18
Extreme 0.18
0.52
3 years
0.18
Extreme 0.18
1.65
5 years
0.05
Extreme 0.05
1.65
10 years
0.05
Extreme 0.05
1.65
More quotes

Managers and Directors - InnoCan Pharma Corporation

Managers TitleAgeSince
Nir Avram FOU
 Founder 71 -
Iris Bincovich FOU
 Founder - 18-05-30
Nelson Halpern DFI
 Director of Finance/CFO - 19-02-19
Members of the board TitleAgeSince
Peter Bloch BRD
 Director/Board Member 64 20-01-21
Ron Abraham Mayron CHM
 Chairman 59 14-05-31
Iris Bincovich FOU
 Founder - 18-05-30
More insiders

Quotes

Date Price Change Volume
24-05-10 0.32 -3.03% 164,850
24-05-09 0.33 +15.79% 543,850
24-05-08 0.285 +1.79% 154,298
24-05-07 0.28 -3.45% 162,100
24-05-06 0.29 +7.41% 157,500

Delayed Quote Canadian Securities Exchange, May 10, 2024 at 03:56 pm EDT

More quotes

Company Profile

Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
Sector
Pharmaceuticals
Calendar
2024-05-27 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
INNOCAN PHARMA CORPORATION Stock InnoCan Pharma Corporation
+3.23% 65.74M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INNO Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW